Group 1 - Hanbang Technology received a decision from the National Intellectual Property Administration declaring the patent rights of Cytiva's "separation medium slurry tank" invalid, reflecting the principle of equal treatment in China's intellectual property protection system [1] - Zhaoyan New Drug announced that its directors and executives plan to reduce their holdings in the company due to personal financial needs, which may raise short-term stock price concerns among investors [2] - Zhixiang Jintai obtained approval for clinical trials of its GR2303 injection, a monoclonal antibody targeting TL1A for treating inflammatory bowel disease, indicating significant clinical development value [3] Group 2 - Lude Medical's actual controller plans to reduce his holdings by 2.48 million shares, accounting for 1.4212% of the total share capital, reflecting urgent personal financial needs [4] - Buchang Pharmaceutical's subsidiary is set to invest in a new company, Shaanxi Buchang Medical Data Pharmaceutical Co., Ltd., aiming to integrate pharmaceutical resources with digital capabilities, aligning with the trend of digital transformation in the pharmaceutical industry [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603127 证券简称：昭衍新药 公告编号：2025-039 北京昭衍新药研究中心股份有限公司 董事、监事及高管减持A股股份计划公告 一、减持主体的基本情况 ■ 注：其他方式是指股权激励及公司资本公积金转增股份等。 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 董监高持股的基本情况 截至本公告披露日，北京昭衍新药研究中心股份有限公司（以下简称"公司"）董事、副总经理孙云霞持 有公司股票2,698,907股，占公司总股本0.3601%；董事、总经理、董事会秘书高大鹏持有公司股票 288,746股，占公司总股本0.0385%；董事、副总经理顾静良持有公司股票269,801股，占公司总股本 0.0360%；监事李叶持有公司股票102,481股，占公司总股本0.0137%；财务总监于爱水持有公司股票 34,104股，占公司总股本0.0046%。上述股份来源于首发前限售股份、股权激励股份及公司资本公积金 转增股份等。 ● 减持计划的主要内容 孙云 ...

Summary of Key Points - The company Zhaoyan New Drug announced a share reduction plan involving several key individuals [2] - The planned reduction will occur from September 30, 2025, to November 28, 2025, through block trading or centralized bidding on the Shanghai Stock Exchange [2] - The total shares to be reduced amount to 848,300, which represents approximately 0.1132% of the company's current total share capital [2]

北京昭衍新药研究中心股份有限公司 董事、监事及高管减持 A 股股份计划公告 证券代码：603127 证券简称：昭衍新药 公告编号：2025-039 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董监高持股的基本情况 孙云霞、高大鹏、顾静良拟自本减持计划公告之日起 15 个交易日后即 2025 年 9 月 30 日至 2025 年 11 月 28 日，通过上海证券交易所大宗交易或集中竞价的 方式分别减持不超过 674,700 股、72,100 股、67,400 股；李叶、于爱水拟自本减 持计划公告之日起 15 个交易日后即 2025 年 9 月 30 日至 2025 年 11 月 28 日，通 过上海证券交易所集中竞价的方式分别减持不超过 25,600 股、8,500 股,前述减持 合计不超过 848,300 股，不超过公司当前总股本的 0.1132%。减持计划实施期间， 公司若发生送红股、转增股本、增发新股或配股等股本除权事项的，减持数量将 进行相应调整。减持价格依据市场价格确定。 | 股东名称 | ...

昭衍新药（603127）(06127)发布公告，孙云霞、高大鹏、顾静良拟自本减持计划公告之日起15个交易 日后即2025年9月30日至2025年11月28日，通过上海证券交易所大宗交易或集中竞价的方式分别减持不 超过67.47万股、7.21万股、6.74万股;李叶、于爱水拟自本减持计划公告之日起15个交易日后即2025年9 月30日至2025年11月28日，通过上海证券交易所集中竞价的方式分别减持不超过2.56万股、8500股,前述 减持合计不超过84.83万股，不超过公司当前总股本的0.1132%。减持计划实施期间，公司若发生送红 股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整。减持价格依据市场价格 确定。 ...

智通财经APP讯，昭衍新药(06127)发布公告，孙云霞、高大鹏、顾静良拟自本减持计划公告之日起15个 交易日后即2025年9月30日至2025年11月28日，通过上海证券交易所大宗交易或集中竞价的方式分别减 持不超过67.47万股、7.21万股、6.74万股;李叶、于爱水拟自本减持计划公告之日起15个交易日后即 2025年9月30日至2025年11月28日，通过上海证券交易所集中竞价的方式分别减持不超过2.56万股、 8500股,前述减持合计不超过84.83万股，不超过公司当前总股本的0.1132%。减持计划实施期间，公司 若发生送红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整。减持价格依 据市场价格确定。 ...

昭衍新药公告，董事副总经理孙云霞拟于2025年9月30日至2025年11月28日通过大宗交易或集中竞价减 持不超过67.47万股；董事总经理高大鹏拟减持不超过72100股；董事副总经理顾静良拟减持不超过 67400股；监事李叶拟减持不超过25600股；财务总监于爱水拟减持不超过8500股；合计不超过84.83万 股，占公司总股本0.1132%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年9月8日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

Group 1 - The A-share innovative drug sector experienced a strong rebound, with the Biopharmaceutical ETF (159839) rising by 4.17% and a trading volume exceeding 44 million yuan [1] - The Biopharmaceutical ETF (159839) has seen a net inflow of over 15 million yuan for two consecutive days [1] - Several innovative drug companies reported significant stock price increases, with notable gains including 9.99% for Zhaoyan New Drug and 7.53% for Changchun High-tech [2] Group 2 - The pharmaceutical industry is experiencing structural differentiation, with a 0.7% decline in revenue and a 1.5% increase in net profit for listed companies in the first half of 2025 [3] - Leading innovative drug companies are achieving profitability, driven by strong sales of key products such as Zebutinib and Furmetinib [3] - The innovative drug sector is expected to benefit from improved policies and a downward trend in global central bank interest rates, which may enhance long-term valuations [4] Group 3 - The CXO industry is entering a recovery phase, with a resurgence in overseas demand expected by the end of 2023, leading to a recovery in domestic head companies' orders in 2024 [5] - The domestic innovative drug assets are progressing into late clinical stages, with increasing validation of clinical data and a clear trend towards internationalization [5]

Core Viewpoint - The medical services sector experienced a significant increase of 3.79% on September 5, with Zhaoyan New Drug leading the gains [1] Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Individual Stock Performance - Zhaoyan New Drug (603127) closed at 34.01, up 9.99% with a trading volume of 578,000 shares and a transaction value of 1.905 billion yuan - Tiger Medical (300347) closed at 66.58, up 6.66% with a trading volume of 146,300 shares and a transaction value of 950 million yuan - Kailaiying (002821) closed at 108.27, up 6.44% with a trading volume of 114,500 shares and a transaction value of 1.213 billion yuan - Posens (301257) closed at 49.20, up 5.81% with a trading volume of 84,700 shares and a transaction value of 407 million yuan - Kanglong Chemical (300759) closed at 31.30, up 5.56% with a trading volume of 615,400 shares and a transaction value of 1.887 billion yuan - WuXi AppTec (603259) closed at 107.40, up 5.36% with a trading volume of 802,300 shares and a transaction value of 8.39 billion yuan - Jiuzhou Pharmaceutical (603456) closed at 19.15, up 5.22% with a trading volume of 441,000 shares and a transaction value of 827 million yuan - ST Biological (000504) closed at 9.68, up 4.99% with a trading volume of 49,800 shares and a transaction value of 4.749 million yuan - Nossger (301333) closed at 58.02, up 4.94% with a trading volume of 56,100 shares and a transaction value of 32.2 million yuan - Boteng Co., Ltd. (300363) closed at 25.90, up 4.73% with a trading volume of 396,800 shares and a transaction value of 1.011 billion yuan [1] Capital Flow - The medical services sector saw a net inflow of 423 million yuan from institutional investors, while retail investors experienced a net outflow of 58.5864 million yuan [1]